ArticleMolecular carcinogenesis2026
Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population.
Article in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer-related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one-third of patients develop biochemical recurrence within 10 years. Although prostate-specific antigen (PSA) is the primary biomarker used for diagnosis and monitoring, additional molecular markers such as PTEN loss and MYC amplification have been investigated to improve prognostic stratification. Liquid biopsy has emerged as a promising tool in oncology, yet the clinical significance of circulating tumor cells (CTCs) in early-stage PCa remains uncertain. This prospective, single-center study included 50 patients with localized prostate cancer from the Brazilian Amazon region who underwent radical prostatectomy in 2023. Peripheral blood samples were collected preoperatively and postoperatively for CTC enumeration and molecular characterization using Cytelligen SET-iFISH and the CellSearch system. PTEN and MYC status were evaluated to further characterize the detected CTC population. CTCs were detected in all patients prior to surgery, with a significant reduction observed after radical prostatectomy (p < 0.001); 88% of patients had no detectable CTCs postoperatively. PTEN loss was identified in 12% of patients, all of whom presented with ISUP grade ≥ 2 disease. MYC amplification was rare, observed in only one patient with Gleason score 7 and concomitant PTEN deletion. These findings suggest that perioperative CTC detection may provide clinically relevant prognostic information in localized PCa. PTEN loss appears to represent an early molecular alteration associated with adverse pathological features. Longer follow-up is needed to determine the predictive value of these biomarkers for recurrence and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.